



Consumer and
Corporate Affairs Canada

Consommation
et Corporations Canada

(11) (A) No. 1 240 929

(45) ISSUED 880823

(52) CLASS 167-199

(51) INT. CL. A61K 31/735⁴

(19) (CA) **CANADIAN PATENT** (12)

(54) Chondroitin Sulfate/Sodium Hyaluronate Compositions

(72) Chang, Allison S.;
Boyd, James E.;
Johnson, Richard M.;
Koch, Harold O.,
U.S.A.

(73) Granted to Cilco, Inc.
U.S.A.

(21) APPLICATION No. 460,409

(22) FILED 940803

(30) PRIORITY DATE U.S.A. ()6/521,575) 830809

No. OF CLAIMS 6 - NO DRAWING

Canada

The invention relates to compositions obtained by adding chondroitin sulfate to sodium hyaluronate in aqueous buffer solution, or sodium hyaluronate to chondroitin sulfate in aqueous buffer solution.

10

This invention relates to compositions for protecting both human and animal endothelial and epithelial cells which are subject to exposure to trauma. More particularly, this invention concerns compositions for protecting endothelial and epithelial cells in anticipation of surgical trauma using chondroitin sulfate/sodium hyaluronate compositions.

Since human corneal endothelial cells are not known to reproduce, it is of vital importance to protect endothelia to prevent cell damage prior to subjection to anticipated trauma, such as surgery. Recent advances in ophthalmic surgery have increased the need to protect corneal endothelial cells which may be subject to irreversible destruction during such surgery. Of particular significance is the need to protect corneal endothelial cells during intraocular lens (IOL) implantation, corneal transplantation and other intraocular surgical operations. Previous work in this field has been directed to protecting corneas with both non-biological and biological polymers.

Macromolecules heretofore employed in the protection of corneas include chondroitin sulfate and



A

sodium hyaluronate. The use of a chondroitin sulfate solution for the protection of corneal surface tissue is described in a "CHONDRON" * product monogram, Kakan Pharmaceutical Company, Ltd., Tokyo, Japan, 1981. The use of sodium hyaluronate as an aid in ophthalmic surgery is described in a "HEALON" * product monogram, Pharmacia Laboratories, Piscataway, New Jersey, 1980.

Solutions containing chondroitin sulfate or sodium hyaluronate alone have not met with complete satisfaction due to inadequate corneal dome maintenance which in turn provides spatial separation of cornea endothelium and surgical instruments, etc., or inadequate corneal endothelial cell protection, respectively.

In view of the above, it would be advantageous to prepare a viscous composition containing chondroitin sulfate and sodium hyaluronate, without the use of any other active material which could irritate or damage corneal endothelial cells.

Viscosity is normally a function of molecular weight at constant solute concentration. It has now been discovered that chondroitin sulfate and sodium hyaluronate may be mixed in aqueous buffer solution in specified ratios to produce a composition having surprisingly high viscosity and offering protection to corneal surface cells during intraocular lens implantation, corneal transplantation, and other intraocular surgical operations, which is superior to that obtained with either of the individual components.

Additionally, the chondroitin sulfate/sodium hyaluronate compositions of the present invention can be administered after trauma as an aid in healing. Surprisingly, it has been found that the chondroitin sulfate/sodium hyaluronate compositions of the present invention exhibit enhanced solution stability and improved physical properties by comparison with the individual components of the composition. These compositions are

* Trade Marks

useful for topical applications as well as for irrigation during surgery.

Thus according to the present invention there is provided a method to protect both human and animal cell layers and tissues subject to exposure to trauma which comprises administering a therapeutically effective amount of a viscous aqueous composition comprising a chondroitin sulfate compound selected from chondroitin sulfate, sodium chondroitin sulfate, potassium chondroitin sulfate, magnesium chondroitin sulfate and calcium chondroitin sulfate, and a hyaluronate selected from sodium hyaluronate, potassium hyaluronate, magnesium hyaluronate and calcium hyaluronate, to said cell layers and tissues prior to said exposure to said trauma, said aqueous composition comprising chondroitin sulfate and sodium hyaluronate in an aqueous buffer, and exhibiting a viscosity which exceeds the individual viscosity of said chondroitin sulfate and sodium hyaluronate.


According to another aspect of the invention, there is provided a process of preparing a viscous aqueous composition comprising a chondroitin sulfate and a metal hyaluronate, useful for protecting both human and animal cell layers and tissues subject to exposure to trauma, which comprises mixing the chondroitin sulfate and metal hyaluronate in aqueous buffer solution, in appropriate relevant proportions to cause a significant increase in viscosity of the mixture.

According to yet another aspect of the invention, there is provided a viscous, aqueous composition of chondroitin sulfate and a metal hyaluronate.

1240929

- 4a -

Both chondroitin sulfate and sodium hyaluronate are glycosaminoglycans, commonly known as mucopolysaccharides. By mixing chondroitin sulfate and sodium hyaluronate in aqueous solution, it has been surprisingly found that the molecules appear to line up and attract each other by hydrogen bonding in the N-acetyl amino group as shown below for a segment of molecular units. The hydrogen bonding interaction is only one of several possible interactions for chondroitin sulfate and sodium hyaluronate.



1240929

-5-

Turley and Roth, Nature, 283, pp. 268-271 (1980), have experimentally demonstrated that chondroitin sulfate-derivatized beads and hyaluronate-derivatized beads are capable of binding interaction with each other
5 and have postulated that the interaction occurs between the carbohydrate chains of the polymers.

It has been surprisingly found that addition of chondroitin sulfate to sodium hyaluronate in aqueous
10 solution or sodium hyaluronate to chondroitin sulfate in aqueous solution dramatically increases the viscosity of mixture. This increase in viscosity appears to be mainly due to increase in molecular weight rather than solute concentration increase. As those in the art are
15 aware, viscosity of solute-solvent is a function of molecular weight and concentration of solute. The hydrogen bonding interaction postulated above between chondroitin sulfate and sodium hyaluronate would result in effectively enlarging the molecular size. Thus,
20 viscosity of the mixture would be increased. The following examples demonstrate the nonlinear or synergistic change in physical properties by mixing of chondroitin sulfate and sodium hyaluronate in aqueous solution, which characterize the present invention. In the follow-
25 ing examples, chondroitin sulfate is abbreviated CS, and sodium hyaluronate is abbreviated SH.

Examples

A chondroitin sulfate/sodium hyaluronate solu-
30 tion was prepared by adding 5.3 grams of chondroitin sulfate to 4.2 grams of sodium hyaluronate in 100 ml of water containing 0.15 grams of monobasic sodium phosphate and 0.45 grams of dibasic sodium phosphate

1240929

-6-

with a trace of sodium chloride. The viscosities of the mixture and individual solutions are shown below.

5

Solution A

5.3 g CS/4.2 SH in 100 ml water with buffer.

Viscosity at 25°C = 71,500 CPS at shear rate less than 2/sec.

10

Solution B

4.2 g SH in 100 ml water with buffer.

15 Viscosity at 25°C = 58,700 CPS at shear rate less than 2/sec.

Solution C

20

5.3 g CS in 100 ml water with buffer.

Viscosity at 25°C = 10 CPS.

25

A negative reaction (i.e., lack of synergistic change) of chondroitin sulfate with methyl cellulose (MC) is demonstrated by the following example. Two grams of chondroitin sulfate is added to 2 grams of methyl cellulose in 100 ml of water.

30

The viscosities of mixture and individual solutions are shown below.

1240929

-7-

Solution D

2 g MC/2 g CS* in 100 ml water.

Viscosity at 25°C = 5,991 CPS at shear rate less
than 50 sec.

*CS is insoluble in solution containing
over 2 g MC.

Solution E

2 g MC in 100 ml water.

Viscosity at 25°C = 5,857 CPS at shear rate less
than 50 sec.

Solution F

2 g CS in 100 ml water.

Viscosity at 25°C = 3.0 CPS.

Due to the molecular structure of methyl
cellulose, the -N-C- groups in chondroitin sulfate could
not possibly form hydrogen bonds with methyl cellulose.
Methyl cellulose lacks -N-C- groups in the molecules.
Hence, addition of chondroitin sulfate in methyl
cellulose solution results in insignificant increase
in viscosity. The observed small increase in viscosity
is due to concentration effect only.

Interaction between chondroitin sulfate and
sodium hyaluronate is believed to take place at any
concentration. However, the synergistic viscosity
effect increases with increasing concentration
because of concentration effect and closeness of

1240929

-8-

molecules for interaction. The solution of chondroitin sulfate/sodium hyaluronate mixture exhibits non-newtonian flow characteristics and has pseudo-plastic behavior. The viscosity of pseudo-plastic substances decrease with increasing shear rates, i.e., relation of viscosity to shear rate is not linear. The following table shows the viscosity plotted against high shear rate at 25°C for solution "A".

	<u>SHEAR RATES (sec⁻¹)</u>			
	<u>250</u>	<u>500</u>	<u>2500</u>	<u>5000</u>
Absolute Viscosity, CPS at 25°C	1,774	1,075	307	181

Most recent data indicate that CS/SH compositions of the invention do not have a yield point.

In the practice of the invention sodium hyaluronate may be used at concentrations from about 0.1 g up to about 10 g in 100 ml water at temperatures from about 4°C to about 37°C. Chondroitin sulfate is also used at concentrations from about 0.1 g up to about 10 g in 100 ml water at temperatures from about 4°C to about 37°C. Within the ranges just described, any quantity of chondroitin sulfate can be added to form binding interaction with hyaluronate and produce physical and flow properties suitable for specific pharmaceutical and ophthalmic uses. Adding 12.6 g of chondroitin sulfate to 10 g sodium hyaluronate in water, the resulting solution has viscosity of over 1 million centipoises at 25°C (for low shear rate below 50 sec⁻¹).

1240929

The aqueous buffer solution used in the practice of the invention includes monobasic sodium phosphate, dibasic sodium phosphate, and sodium chloride mixed to form an aqueous buffer to maintain pH of about 7 to about 8.0 and osmolarity of 300 - 350 mOsmol/kg. By raising the buffer concentration of monobasic sodium phosphate and dibasic sodium phosphate, the ionic strength of chondroitin sulfate/hyaluronate solution is increased. The kinetic rate constant of molecule interaction between chondroitin sulfate and hyaluronate is increased by raising ionic strength and temperature. This invention comprises concentrations of dibasic sodium phosphate and monobasic sodium phosphate from 0.1 g/100 ml to 5 g/100 ml and pH range of 7.0 to 8.0 at reaction temperatures between 4°C and 40°C. The following example shows the effect of buffer on the viscosity or molecular weight of complex molecules for 5.3 g CS/4.2 g SH in 100 ml water:

Buffer 1: Dibasic sodium phosphate - 4.5 mg/ml
Sodium dihydrogen phosphate hydrate - 1.5 mg/ml
Viscosity of compositions of the present invention at 1 second and 25°C is 68,878 cps.

Buffer 2: Dibasic sodium phosphate - 7.5 mg/ml
Sodium dihydrogen phosphate hydrate - 1.0 mg/ml
Viscosity of compositions of the present invention at 1 second and 25°C is 115,011 cps.

The solution of chondroitin sulfate/hyaluronate mixture not only exhibits viscoelastic but also rheopectic behavior (i.e., viscosity increases

1240929

-10-

with time at constant shear rate). At constant shear rate of 100 sec^{-1} for solution A, shear stress increases from 435 pascals to 452 pascals in 3 minutes. Both chondroitin sulfate and hyaluronate are helical straight chain molecules. In highly viscous environments the lower the temperature the less mobility both molecules will have to align the N-acetylamine groups for mutual interaction. This interaction may take place at a very slow rate. However, the mutual interaction increases with raising of the temperature due to kinetic rate increase and better mobility of molecules to align the N-acetylamine groups for hydrogen bonding. When shear energy is added to the molecules, the kinetic energy of the molecules increases and the molecules are more easily aligned or oriented for bonding interaction. Thus, the viscosity is increased when shear energy is added to the mixture and/or the mixture is subjected to an increase in temperature, resulting in high molecular weight material.

Although the invention has been described in detail with reference to chondroitin sulfate and sodium hyaluronate, it is also applicable to sodium, potassium, magnesium and calcium chondroitin sulfates, and to potassium, magnesium and calcium hyaluronates.

It is understood that various other modifications will be apparent to and can readily be made by those skilled in the art without departing from the scope and spirit of this invention. Accordingly, it is not intended that the scope of the claims appended hereto be limited to the description as set forth herein, but rather that the claims be construed as encompassing all the features of patentable novelty which reside in the present invention, including all features which would be treated as equivalents thereof by those skilled in the art to which this invention pertains.

1240929

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:

1. A process of preparing a viscous aqueous composition comprising a chondroitin sulfate and a metal hyaluronate, useful for protecting both human and animal cell layers and tissues subject to exposure to trauma, which comprises mixing the chondroitin sulfate and metal hyaluronate in aqueous buffer solution, in appropriate relevant proportions to cause a significant increase in viscosity of the mixture.
2. The process of claim 1, wherein the metal hyaluronate is employed at concentrations from about 0.1 g to about 10 g per 100 ml water, and the chondroitin sulfate is employed at concentrations from about 0.1 to about 10 g per 100 ml water.
3. The process of claim 1, wherein the metal hyaluronate is selected from sodium hyaluronate, magnesium hyaluronate, calcium hyaluronate and potassium hyaluronate, and the chondroitin sulfate is selected from sodium chondroitin sulfate, potassium chondroitin sulfate, calcium chondroitin sulfate and magnesium chondroitin sulfate.
4. A viscous, aqueous composition of chondroitin sulfate and a metal hyaluronate.
5. A viscous, aqueous composition of a metal hyaluronate, at a concentration from about 0.1 g to about 10 g per 100 ml water, and chondroitin sulfate, at a concentration from about 0.1 g per 100 ml water.
6. A viscous aqueous composition of at least one metal hyaluronate selected from sodium hyaluronate, magnesium hyaluronate, calcium hyaluronate and potassium hyaluronate, and at least one chondroitin sulfate selected from sodium chondroitin sulfate, potassium chondroitin sulfate, calcium chondroitin sulfate and magnesium chondroitin sulfate.

//



460409

460,409-1
APPLICATION NO. - DEMAND N°

FILED - OFFICE LE
840803

U.S.A. (06/521,573) 830809

APPLICANT - DEMANDATEUR
CILCO, Inc.

US

INVENTOR - INVENTEUR
Cheng, Allison S.; Boyd, James E.; Johnson,
Richard M.; Koch, Harold O.

INVENTION
Chondroitin Sulfate/Sodium Hyaluronate
Compositions

35010-006

AGENT
Brown & Orange
Hirons, Rogers & Co.
Box 43,
Toronto-Dominion Bank Tower
Toronto-Dominion Centre
Toronto, Ontario
M5X 1E6

6 INT. CL.

A61K 21/735

3963

28

CLASS	CLASS	CLASS	CLASS	CLASS	CLASS
CLASS - CLASS	CLASS - CLASS	CLASS - CLASS	CLASS - CLASS	CLASS - CLASS	CLASS - CLASS

ORDER - VENT	FORM - FORM	NOTES OF ALLOWANCE
ORDER - VENT	FORM - FORM	NOTES OF ALLOWANCE

DEC 15 1987 6

REPORTS AND AMENDMENTS - RAPPORTS ET AMENDEMENTS

REPT. FILED
NOV 19 1985
REPT. FILED
FEB 18 1987

CLAIMS PUBLISHED - REPERCUSSIONS PUBLIEES

1/4

ALLOWED - ACCÉPTÉ

DEC - 2 1987

SIGNATURE OF EXAMINER - SIGNATURE D'EXAMINATEUR
Ray Kanaoka

WITHDRAWN FROM ALL OFFICES - RETIRÉ DE L'ACCÉPTATION

RESTORED OR REINSTITUTED - RESTAURÉ OU RÉTABLI

SECOND ALLOWANCE - REACCÉPTATION

SIGNATURE OF EXAMINER - SIGNATURE D'EXAMINATEUR

PATENT NO.
BREVET NO

1240929

AUG 23 1988

ISSUED
EMIS LE

460409

460,409-1
APPLICATION NO. - DEMANDE N°
840803

PRIORITY DATE - DATE DE PRIORITE
U.S.A. (06/321, 373) 830809

APPLICANT - DEMANDATEUR
CILCO, Inc.

INVENTOR - INVENTEUR
Chang, Allison S.; Boyd, James E.; Johnson, Richard H.; Koch, Harold O.
Chondroitin Sulfate/Sodium Hyaluronate Compositions

3963
53010-006
Brown & Orange
Hirons, Rogers & Scott
Box 48,
Toronto-Dominion Bank Tower
Toronto-Dominion Centre
Toronto, Ontario
M5K 1E6

DIVISION	CLASS - CLASSE	NO. OF CLAIMS
D2	167	199

ORIGINAL	CLASS	NO. OF CLAIMS	CLASS - CLASSE	NO. OF CLAIMS	NO. OF CLAIMS

GREEN - VERT	PINK - ROSE	NOTICE OF ALLOWANCE ISSUED AND D'ACCEPTATION CÉDÉE LE
		DEC 15 1987 6

REPORTS AND AMENDMENTS - RAPPORTS ET AMENDEMENTS

REPT. NO. 19 NOV 19 1985
APP. EXP. FEB 18 1987
A. *Therapeutic*
B. *Drug Utilization*

CLASS PUBLISHED - REVOCATIONS PUBLIÉES
1/14
ALLOWED - ACCEPTÉ
DEC - 2 1987

SIGNATURE OF EXAMINER - SIGNATURE D'EXAMINATEUR
Ray Karam
WITHDRAWN FROM ALLOWANCE - RETIRÉ DE L'ACCEPTATION

RESTORED OR REINSTATED - RESTAURÉ OU RÉTABLI

SECOND ALLOWANCE - RÉACCEPTATION

PATENT NO.
BREVET NO

1240929

AUG 23 1988

Patent appl. no.
Demande originale n°

Int.
Ext.

Discipline (107)
Divulguée (107) acceptable
Dessins (107) acceptable(s)
Dessins (107) acceptable(s)
Claims (107)
Revendicatifs (107)

Examiner
Examineur

Date

FIELD OF SEARCH
CHAMP DE RECHERCHE

CROSS REFERENCE
RENYOI

CORRESPONDING FOREIGN PATENTS
BREVETS ETRANGERS CORRESPONDANTS

NOTES

DWGS. CORR. DESSINS	TOTAL
	RECEIVED VERBES
	BALANCE SOLDE
	REMARKS REMARQUES
	DETAILS DETAILS